2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-122153
    VSN-16 863713-78-4 98%
    VSN-16 is a cannabinoid receptor agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis.
    VSN-16
  • HY-122732
    OADS 5970-15-0 98.25%
    OADS is a Chloride channel antiporter (ClC-ec1) inhibitor (IC50: 29 μM). OADS specifically inhibits the ClC-ec1 antiporter but not the ClC-1 channel. OADS can be used for research of osteoporosis and neurodegenerative and cardiovascular diseases.
    OADS
  • HY-122949
    Momordicine I 91590-76-0
    Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes.
    Momordicine I
  • HY-12533A
    Disopyramide phosphate 22059-60-5 99.85%
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action.
    Disopyramide phosphate
  • HY-125641
    AL-34662 210580-75-9 99.19%
    AL-34662 is a selective 5-HT2A receptoragonist (IC50: 0.77 nM and 1.5 nM for rat and human 5-HT2 receptor). AL-34662 is also a weak α-1D adrenergic agonist activity (EC50:0.4 μM). AL-34662 is an ocular hypotensive agent.
    AL-34662
  • HY-138875
    Tetraacetylphytosphingosine 13018-48-9 99.90%
    Tetraacetylphytosphingosine is a sphingolipid metabolite produced by phytosphingosine acetylation. Tetraacetylphytosphingosine exerts its inhibitory action on angiogenesis through the inhibition of MAPK activation and intracellular calcium increase. Tetraacetylphytosphingosine induces apoptosis in HaCaT cells.
    Tetraacetylphytosphingosine
  • HY-14268R
    Febuxostat (Standard) 144060-53-7 99.70%
    Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat (Standard)
  • HY-153595
    DAPK-IN-2 304000-05-3 98.02%
    DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases.
    DAPK-IN-2
  • HY-161940
    PCSK9-IN-30 98%
    PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases.
    PCSK9-IN-30
  • HY-163689
    Vicadrostat 1868065-21-7 98.67%
    Vicadrostat is an aldosterone synthase inhibitor (IC50=48 nM). Vicadrostat can be used for research in kidney diseases and cardiovascular diseases.
    Vicadrostat
  • HY-50667R
    Apixaban (Standard) 503612-47-3 99.95%
    Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
    Apixaban (Standard)
  • HY-50903R
    Rivaroxaban (Standard) 366789-02-8 99.72%
    Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    Rivaroxaban (Standard)
  • HY-A0023R
    Alogliptin Benzoate (Standard) 850649-62-6 99.31%
    Alogliptin (Benzoate) (Standard) is the analytical standard of Alogliptin (Benzoate). This product is intended for research and analytical applications. Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.
    Alogliptin Benzoate (Standard)
  • HY-B0279S
    Ramipril-d5 1132661-86-9 99.0%
    Ramipril-d5 is the deuterium labeled Ramipril. Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
    Ramipril-d5
  • HY-B0381B
    Levobetaxolol hydrochloride 116209-55-3 99.31%
    Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.
    Levobetaxolol hydrochloride
  • HY-B0686B
    Eptifibatide acetate 881997-86-0 98%
    Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
    Eptifibatide acetate
  • HY-N0684R
    Vitamin K1 (Standard) 84-80-0
    Vitamin K1 (Standard) is the analytical standard of Vitamin K1. This product is intended for research and analytical applications. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.
    Vitamin K1 (Standard)
  • HY-N11222
    Nonanoylcarnitine 151109-67-0 99.87%
    Nonanoylcarnitine is a metabolite associated with chronic environmental exposure to polycyclic aromatic hydrocarbons (PAH) and fragmented QRS waves in acute myocardial infarction. Nonanoylcarnitine can be used as a potential biomarker for the metabolic outcome of PAH exposure and the prognosis of acute myocardial infarction.
    Nonanoylcarnitine
  • HY-U00134
    Benzcyclane 2179-37-5 99.39%
    Benzcyclane (Bencyclane; Benzcyclan) is a platelet aggregation inhibitor and a vasodilator effective in a variety of peripheral circulation disorders.
    Benzcyclane
  • HY-U00308
    5-LOX-IN-4 125235-15-6 98.06%
    5-LOX-IN-4 is a 5-Lipoxygenase inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.
    5-LOX-IN-4
Cat. No. Product Name / Synonyms Application Reactivity